Emergence of ICOS hi CD4 T Cells is Associated with Tumor Reduction, Progression-Free Survival, and Overall Survival in Advanced Cancer Patients Treated with Vopratelimab, an ICOS Agonist
Johan Baeck,
VP, Clinical Development & Medical Affairs,
Jounce Therapeutics
Vopratelimab is an ICOS agonist antibody intended to stimulate primed
CD4 T effector cells. In the ICONIC trial, peripheral T cell phenotyping
demonstrated emergence of an ICOShi subset of activated CD4 T
effector cells associated with tumor reductions and improved PFS and
OS, with expansion of peripheral T cell receptor clones found in the
original matched archival tumor. Future development focuses on settings
in which ICOShi CD 4 T effector cells are primed to respond to vopratelimab.
|
|
